Skip to main content

Month: December 2020

Statkraft to build, sell and manage two Irish wind farms

(Cork/London/Oslo 21 December 2020) Statkraft has decided to construct Cloghan and Taghart wind farms in Ireland. In addition, the company has agreed to sell the wind farms to Greencoat Renewables PLC while retaining responsibility for the construction and the long-term operation and management, in line with Statkraft’s strategy to build, sell, operate and trade power.Cloghan (37.8MW) is located in County Offaly and Taghart (25.2MW) in County Cavan in Ireland. Construction will commence early 2021. Statkraft will manage the construction of both wind farms and will provide operational management services for the wind farms in the operations phase. The ownership of the assets will be transferred to Greencoat Renewables PLC when they become operational in 2022. The total value of the project, including construction costs, is €123 million.Commenting...

Continue reading

Statkraft skal bygge og selge to vindparker i Irland

(Cork/London/Oslo, 21. desember 2020) Statkraft har besluttet å bygge vindparkene Cloghan og Taghart i Irland. I tillegg har selskapet avtalt å selge de to vindparkene til investeringsfondet Greencoat Renewables PLC så snart de er ferdigstilt. Statkraft vil forvalte kraften og levere eieroppfølgingstjenester i driftsfasen, i tråd med Statkraft’s strategi om å bygge, selge og drifte kraftverk, samt å drive krafthandel.Byggingen av vindparkene Cloghan (37,8 MW) i Offaly og Taghart (25,2 MW) i Cavan i Irland tar til i første halvdel av 2021. Statkraft vil være ansvarlig for utbyggingen. Eierskapet til anleggene overføres til Greencoat Renewables PLC ved idriftsettelse i 2022, og Statkraft vil levere eieroppfølgings- og kraftsalgstjenester i driftsfasen. Avtalen har en verdi på 123 millioner euro.– Statkraft spiller en ledende rolle...

Continue reading

Heeros Oyj: Karoliina Beltrami nimetty Heeroksen johtoryhmään uutena jäsenenä

Karoliina Beltrami nimetty Heeroksen johtoryhmään uutena jäsenenäHEEROS OYJ Yhtiötiedote 21.12.2020 klo 9.00Karoliina Beltrami nimetty Heeroksen johtoryhmään uutena jäsenenäHeeroksen johtoryhmään on nimitetty uutena jäsenenä Director, People & Culture Karoliina Beltrami. Karoliina Beltrami raportoi tehtävissään toimitusjohtajalle.Beltramin päävastuulla on Heeroksen henkilöstöasiat, organisaatiokulttuurin ja työhyvinvoinnin kehittäminen sekä yhtiön sisäinen viestintä. Beltrami on ollut yhtiön palveluksessa vuodesta 2019 alkaen ja hän on aiemmin toiminut Heeroksella HR Managerina.Beltrami on koulutukseltaan kauppatieteiden maisteri ja ennen siirtymistään Heerokselle hän on toiminut eri teknologia-alan yrityksissä sekä taloushallinnon että HR:n tehtävissä.”Henkilöstöasioiden painoarvo kasvaa Heeroksen uuden kasvustrategian myötä. Osana...

Continue reading

EasyVista : communiqué relatif à la mise à disposition de la note en réponse et des informations relatives aux caractéristiques, notamment juridiques, financières et comptables d’EasyVista dans le cadre de l’offre publique d’achat

communiqué relatif à la mise à disposition de la note en réponse et des informations relatives aux caractéristiques, notamment juridiques, financières et comptables d’EasyVista dans le cadre de l’offre publique d’achatPièce jointeEasyVista – CP de mise à disposition (note en réponse, autres informations EasyVista)

Continue reading

AB Science announces the success of its capital raise for a total amount of 15 million euros

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN – THIS PRESS RELEASE IS NOT AN OFFER TO SUBSCRIBE AND IS FOR INFORMATION ONLYPRESS RELEASEAB SCIENCE ANNOUNCES THE SUCCES OF ITS CAPITAL RAISE FOR A TOTAL AMOUNT OF 15.0 MILLION EUROS·10.5 million euros raised through a private placement and accelerated book-building procedure, without discount, at a price of 14.42 euros per ordinary share. ·This private placement triggers the conversion of the convertible bonds announced on October 29, 2020 with a nominal value of 4.5 million euros.         Paris, France – December 21, 2020AB Science (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces a capital raise of 10.5 million euros by way of issuance of 728,156 new ordinary shares (the “New Shares”)....

Continue reading

AB Science annonce aujourd’hui le succès de son augmentation de capital pour un montant global d’environ 15,0 millions d’euros

NE DOIT PAS ETRE DISTRIBUE OU PUBLIE, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMERIQUE, AU CANADA, EN AUSTRALIE OU AU JAPON – CE COMMUNIQUE DE PRESSE NE CONSTITUE PAS UN DOCUMENT D’OFFRE ET A UN CARACTERE PUREMENT INFORMATIFCOMMUNIQUE DE PRESSEAB SCIENCE ANNONCE LE SUCCES DE SON AUGMENTATION DE CAPITAL POUR UN MONTANT GLOBAL D’ENVIRON 15,0 MILLIONS D’EUROS·10,5 millions d’euros levés par un placement privé, sans décote, au prix de 14,42 euros par action ordinaire nouvelle, au moyen de la construction accélérée d’un livre d’ordres. ·Ce placement privé entraîne la conversion des obligations convertibles dont l’émission a été annoncée le 29 octobre 2020 pour un montant de 4,5 millions d’euros.Paris, France – 21 décembre 2020AB Science (la « Société » ou « AB Science », Euronext – FR0010557264 – AB) annonce aujourd’hui une augmentation...

Continue reading

Ovaro Kiinteistösijoitus Oyj:n strategian päivitys vuosille 2021-2023

Ovaro Kiinteistösijoitus OyjLuokka: sisäpiiritieto                                                                                                            Ovaro Kiinteistösijoitus Oyj:n strategian päivitys vuosille 2021-2023Ovaro Kiinteistösijoitus Oyj päivitti strategiaansa ja siirtyy strategiakaudella 2021-2023 saneerausvaiheesta aktiiviseen kiinteistövarallisuuden hoitoon ja hankekehitykseen. Ovaron tavoitteena on lähiaikoina käynnistää sekä uusia kiinteistöhankkeita että nykyisen kiinteistökannan modernisointeja ja lisäksi uusia rahoitusrakenteensa.Ovaro tarkastelee aktiivisesti omistuksiaan ja luopuu kohteista, joille yhtiö ei näe riittävästi tuottopotentiaalia.Strategiajakson keskeiset tavoitteet:Operatiivinen tuloksen (EPRA) merkittävä paraneminenTuottojen saaminen vuokrausliiketoiminnan lisäksi myös kiinteistöjen kehityshankkeista.Ydinsalkun...

Continue reading

Mowi ASA: Enters into a Share Purchase Agreement to divest its 50% stake in DESS Aquaculture Shipping

With reference to previously announced potential divestment of DESS Aquaculture Shipping.Mowi is pleased to announce an agreement to divest its 50% stake in DESS Aquaculture Shipping to an entity controlled by Antin Infrastructure Partners.Mowi has invested EUR 60m in DESS Aquaculture Shipping to date and our share of proceeds is EUR 115m. Mowi will recognise a gain of approximately EUR 55m in Financial EBIT in our P&L upon closing.Closing of the transaction is subject to, inter alia, customary closing conditions.This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Continue reading

Kalmar plans to transfer part of its crane engineering in China to Etteplan

CARGOTEC CORPORATION, PRESS RELEASE, 21 DECEMBER 2020 AT 8.00 AM (EET)Kalmar, part of Cargotec, plans to transfer part of its crane engineering in China to Etteplan, a globally operating engineering company. With the planned long-term agreement Kalmar aims to improve the efficiency of its crane engineering operations in China by ensuring scalability and cost competitiveness.The parties have signed an agreement regarding the services to be provided by Etteplan. As a consequence, approximately 70 Kalmar engineering employees in China are planned to move to Etteplan. The planned transfer is expected to take place on 1 January 2021. After that, the transferring employees will initially continue to work from their current locations in their current roles and tasks. “We are aiming to improve our competitiveness by outsourcing part of the crane...

Continue reading

Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness

Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studiesMore than half of participants in the faricimab personalised dosing arms had extended time between treatments to 16 weeks at year one – the first time this level of durability has been achieved in a phase III diabetic macular edema studyFaricimab is the first investigational bispecific antibody designed for the eye and targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditionsFaricimab was generally well-tolerated, with no new safety signals identifiedBasel, 21 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.